Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review

[1]  C. Bao,et al.  Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. , 2020, Rheumatology.

[2]  M. Plana,et al.  Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. , 2020, Seminars in arthritis and rheumatism.

[3]  S. Rosenzweig,et al.  Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. , 2019, Brain : a journal of neurology.

[4]  M. Takemura,et al.  Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum , 2019, Clinical Rheumatology.

[5]  A. Mammen,et al.  Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis , 2019, Annals of the rheumatic diseases.

[6]  W. Stenzel,et al.  JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis , 2018, Brain : a journal of neurology.

[7]  R. Yip,et al.  Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis , 2018, Clinical Rheumatology.

[8]  P. Lachenbruch,et al.  2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups , 2017, Annals of the rheumatic diseases.

[9]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[10]  N. Wulffraat,et al.  Consensus-based recommendations for the management of juvenile dermatomyositis , 2016, Annals of the rheumatic diseases.

[11]  S. Takezaki,et al.  Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. , 2015, Rheumatology.

[12]  H. Yamanaka,et al.  Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies , 2015, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[13]  P. Mathiesen,et al.  Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. , 2014, Rheumatology.

[14]  S. Danoff,et al.  Anti–Melanoma Differentiation–Associated Protein 5–Associated Dermatomyositis: Expanding the Clinical Spectrum , 2013, Arthritis care & research.

[15]  Xiaoyi Ding,et al.  Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti–melanoma differentiation–associated gene 5 antibody , 2012, Arthritis care & research.

[16]  S. Yamasaki,et al.  The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. , 2012, Rheumatology.

[17]  E. Baechler,et al.  Type I interferon pathway in adult and juvenile dermatomyositis , 2011, Arthritis research & therapy.

[18]  L. Chung,et al.  The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. , 2011, Journal of the American Academy of Dermatology.

[19]  B. Feldman,et al.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference , 2010, Arthritis care & research.

[20]  T. Fujita,et al.  RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. , 2009, Arthritis and rheumatism.

[21]  T. Nishikawa,et al.  Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. , 2005, Arthritis and rheumatism.

[22]  A. Dyer,et al.  US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. , 2003, Arthritis and rheumatism.

[23]  R. Sontheimer.  Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? , 2002, Journal of the American Academy of Dermatology.

[24]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .